SEC Filing Summary: Form 6-K
Business Context and Reporting Period
This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of May 2024, with a specific reporting date of May 16, 2024. The registrant is a foreign private issuer headquartered in Mechelen, Belgium, filing under Rule 13a-16 of the Securities Exchange Act of 1934. The filing incorporates by reference a press release dated May 16, 2024 (Exhibit 99.1).
Financial Metrics
The filing text provided does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing serves solely to distribute the attached press release.
Material Changes
No material changes to financial performance or operations are detailed in the text of this Form 6-K. The document references a press release for specific updates but does not summarize the content of that release.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It notes that the information in the press release is incorporated into various Registration Statements on Form S-8.
Key Facts for Investor Verification
- Company Identity: Verify that the filing pertains to Galapagos NV, not Lakefront Biotherapeutics NV.
- Press Release Content: Review Exhibit 99.1 (the May 16, 2024 press release) for the actual substance of the announcement, as the Form 6-K text contains no operational details.
- Registration Statements: Note that this information is incorporated into multiple Form S-8 registration statements (File Nos. 333-204567 through 333-275886).
- Financial Data: Acknowledge that this specific filing does not provide quarterly or annual financial metrics.